WO2000006185A2 - Methods of using lanreotide, a somatostatin analogue - Google Patents

Methods of using lanreotide, a somatostatin analogue Download PDF

Info

Publication number
WO2000006185A2
WO2000006185A2 PCT/US1999/017294 US9917294W WO0006185A2 WO 2000006185 A2 WO2000006185 A2 WO 2000006185A2 US 9917294 W US9917294 W US 9917294W WO 0006185 A2 WO0006185 A2 WO 0006185A2
Authority
WO
WIPO (PCT)
Prior art keywords
disease
cys
syndrome
condition
lanreotide
Prior art date
Application number
PCT/US1999/017294
Other languages
French (fr)
Other versions
WO2000006185A3 (en
Inventor
Jacques-Pierre Moreau
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR9912609-5A priority Critical patent/BR9912609A/en
Priority to AU52447/99A priority patent/AU770193B2/en
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.
Priority to NZ509348A priority patent/NZ509348A/en
Priority to EP99937658A priority patent/EP1100532A2/en
Priority to PL99346361A priority patent/PL346361A1/en
Priority to KR1020017001277A priority patent/KR20010071071A/en
Priority to MXPA01000969A priority patent/MXPA01000969A/en
Priority to JP2000562039A priority patent/JP2002521456A/en
Priority to CA002335654A priority patent/CA2335654A1/en
Priority to HU0102839A priority patent/HUP0102839A3/en
Priority to IL14083799A priority patent/IL140837A0/en
Publication of WO2000006185A2 publication Critical patent/WO2000006185A2/en
Publication of WO2000006185A3 publication Critical patent/WO2000006185A3/en
Priority to NO20010481A priority patent/NO324123B1/en
Priority to AU2004201783A priority patent/AU2004201783A1/en
Priority to IL181349A priority patent/IL181349A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention is directed to a method of treating one or more of the following diseases and/or conditions in a patient in need thereof, which comprises the administration of the compound of the formula H- ⁇ -D-Nal-Cys- Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 (also known as lanreotide), where the two Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, most preferably the acetate salt of the compound, in the treatment of certain diseases and/or conditions such as gastroenterological conditions and/or diseases, such as Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, upper gastrointestinal bleeding, postpra
  • Lanreotide is an analog of somatostatin and is known to inhibit growth hormone release as well as inhibit insulin, glucagon and pancreatic exocrine secretion.
  • U.S. Patent No. 4,853,371 discloses lanreotide, a method for making it and a method for inhibiting the secretion of growth hormone, insulin, glucagon and pancreatic exocrine secretion.
  • U.S. Patent No. 5,147,856 discloses the use of lanreotide of treating restenosis.
  • U.S. Patent No. 5,411 ,943 discloses the use of lanreotide for treating hepatoma.
  • U.S. Patent No. 5,073,541 discloses the use of lanreotide for treating lung cancer.
  • U.S. Application No. 08/089,410 filed July 9, 1993 discloses the use of lanreotide for treating melanoma.
  • U.S. Patent No. 5,504,069 discloses the use of lanreotide for inhibiting the accelerated growth of a solid tumor.
  • U.S. Patent No. 5,688,418 discloses the use of lanreotide for prolonging the survival of pancreatic cells.
  • PCT Application No. PCT/US97/14154 discloses the use of lanreotide for treating fibrosis.
  • This invention is directed to a method of treating a disease or condition which comprises administering to a patient in need thereof an effective amount of the compound H- ⁇ -D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 , where the two Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular de
  • a preferred method of the immediately foregoing method is where the acetate salt of H- ⁇ -D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 is administered.
  • a preferred method of the immediately foregoing method is where the disease or condition is selected from the group consisting of VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, hypersecretory diarrhea, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, diabetic neuropathy, meningioma and cancer cachexia.
  • a preferred method of the immediately foregoing method is where the disease or condition treated is selected from the group consisting of VIPoma, nesidoblastosis, hypersecretory diarrhea, irritable bowel syndrome, small bowel obstruction and diabetic neuropathy.
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the acetate salt of H- ⁇ -D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 to treat a disease or condition wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Page
  • Lanreotide is readily prepared according to the procedure disclosed in U.S. Patent No. 4,853,371 , or the procedure disclosed in U.S. Patent No. 5,411 ,943, the teachings of which are incorporated herein by reference. Lanreotide is currently marketed as the acetate salt in a 30 mg long-acting form and is available from Ipsen Biotech, Paris, France.
  • somatostatin As is well known to those skilled in the art, the known and potential uses of somatostatin are varied and multitudinous. Somatostatin is known to be useful in the treatment of the diseases and/or conditions listed hereinbelow. The varied uses of somatostatin may be summarized as follows: Cushings Syndrome (see Clark, R.V. et al, Clin. Res. 38, p. 943A, 1990); gonadotropinoma (see Ambrosi B., et al., Acta Endocr. (Copenh.) 122, 569-576, 1990); hyperparathyroidism (see Miller, D., et al., Canad. Med. Ass. J., Vol. 145, pp.
  • Paget's disease see, Palmie , G.M.A., et al., J. of Bone and Mineral Research, 7, (Suppl. 1), p. S240 (Abs. 591 ), 1992
  • VIPoma see Koberstein, B., et al., Z. Gastroenterology, 28, 295-301 , 1990 and Christensen, O, Acta Chir. Scand. 155. 541-543, 1989
  • nesidioblastosis and hyperinsulinism see Laron, Z., Israel J. Med. Sci., 26, No. 1 , 1-2, 1990, Wilson, D.C., Irish J. Med. Sci., 158, No.
  • pancreatitis see Tulassay, Z., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A238, 1990); Crohn's Disease (see Fedorak, R.N., et al., Can. J. Gastroenterology, 3, No. 2, 53-57, 1989); systemic sclerosis (see Soudah, H., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A129, 1990); thyroid cancer (see Modigliani, E., et al., Ann., Endocr.
  • pancreatic pseudocysts and ascites see Hartley, J.E., et al., J. Roy. Soc. Med., 85, pp. 107-108, 1992
  • leukemia see Santini, et al., 78, (Suppl. 1), p. 429A (Abs. 1708), 1991
  • meningioma see Koper, J.W., et al., J. Clin. Endocr. Metab., 74, pp. 543-547, 1992
  • cancer cachexia see Bartlett, D.L., et al., Surg. Forum., 42, pp. 14-16, 1991.
  • the contents of the foregoing references are incorporated herein by reference.
  • lanreotide itself was particularly useful in treating the conditions, disorders and disease noted hereinabove.
  • Lanreotide or a pharmaceutically-acceptable salt thereof can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
  • nasal, vaginal, rectal, sublingual or topical routes of administration can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
  • Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
  • Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
  • non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria- retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
  • Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
  • the dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 25 ?g/kg/day to 100 mg/kg/day of body weight daily are administered as a single dose or divided into multiple doses to humans and other animals, e.g., mammals, to obtain the desired therapeutic effect.
  • a preferred general dosage range is 250 ?g/kg/day to 5.0 mg/kg/day of body weight daily which can be administered as a single dose or divided into multiple doses.
  • Lanreotide can be administered in a sustained release composition such as those described in the following patents. Among those formulations, 14-day or 28-day slow release formulations will be preferred.
  • U.S. Patent No. 5,672,659 teaches sustained release compositions comprising Lanreotide and a polyester.
  • U.S. Patent No. 5,595,760 teaches sustained release compositions comprising Lanreotide in a gelable form.
  • U.S. Application No. 08/929,363 filed September 9, 1997 teaches polymeric sustained release compositions comprising Lanreotide and chitosan.
  • U.S. Application No. 08/740,778 filed November 1 , 1996 teaches sustained release compositions comprising Lanreotide and cyclodexthn.
  • U.S. Application No. 09/015,394 filed January 29, 1998 teaches absorbable sustained release compositions of Lanreotide. The contents of the foregoing patents and applications are incorporated herein by reference.
  • immediate or of sustained release compositions depends on the type of indications aimed at. If the indication consists of an acute or over- acute disorder, a treatment with an immediate form will be preferred over the same with a prolonged release composition. On the contrary, for preventive or long-term treatments, a prolonged release composition will generally be preferred.
  • upper gastrointestinal bleeding will correspond an acute or over-acute treatment with a dosage of 80 to 120 ?g/day per person during approximately 5 days.
  • preventive treatment against recurrence can be performed using lanreotide sustained release forms as an adjuvant to usual treatments; for this type of treatment, 14-day sustained release forms with a total dosage of approximately 30 mg lanreotide or 28-day lanreotide forms can be used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to a method of treating one or more of the following disease and/or conditions, which comprises administering to a patient in need thereof the compound H-g(b)-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, where the Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, most preferably the acetate salt of the compound, in the treatment of certain diseases and/or conditions such as gastroenterological conditions and/or diseases, endocronological diseases and/or conditions, various types of cancers and conditions associated with cancer such as cancer cachexia and in the treatment of hypotension and panic attacks.

Description

METHODS OF USING A SOMATOSTATIN ANALOGUE Background of the Invention
The present invention is directed to a method of treating one or more of the following diseases and/or conditions in a patient in need thereof, which comprises the administration of the compound of the formula H-β-D-Nal-Cys- Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 (also known as lanreotide), where the two Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, most preferably the acetate salt of the compound, in the treatment of certain diseases and/or conditions such as gastroenterological conditions and/or diseases, such as Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, upper gastrointestinal bleeding, postprandial portal venous hypertension especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux and in treating endocrinological diseases and/or conditions, such as Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, and polycystic ovary disease; in treating various types of cancer such as thyroid cancer, leukemia, meningioma and conditions associated with cancer such as cancer cachexia; in the treatment of such conditions as hypotension such as orthostatic hypotension and postprandial hypotension and panic attacks.
Lanreotide is an analog of somatostatin and is known to inhibit growth hormone release as well as inhibit insulin, glucagon and pancreatic exocrine secretion.
U.S. Patent No. 4,853,371 discloses lanreotide, a method for making it and a method for inhibiting the secretion of growth hormone, insulin, glucagon and pancreatic exocrine secretion.
U.S. Patent No. 5,147,856 discloses the use of lanreotide of treating restenosis. U.S. Patent No. 5,411 ,943 discloses the use of lanreotide for treating hepatoma.
U.S. Patent No. 5,073,541 discloses the use of lanreotide for treating lung cancer. U.S. Application No. 08/089,410 filed July 9, 1993 discloses the use of lanreotide for treating melanoma.
U.S. Patent No. 5,504,069 discloses the use of lanreotide for inhibiting the accelerated growth of a solid tumor.
U.S. Application No. 08/854,941 filed May 13, 1997, discloses the use of lanreotide for decreasing body weight.
U.S. Application No. 08/854,943 filed May 13, 1997, discloses the use of lanreotide for treating insulin resistance and Syndrome X.
U.S. Patent No. 5,688,418 discloses the use of lanreotide for prolonging the survival of pancreatic cells. PCT Application No. PCT/US97/14154 discloses the use of lanreotide for treating fibrosis.
U.S. Application No. 08/855,311 filed May 13, 1997, discloses the use of lanreotide for treating hyperlipidemia.
U.S. Application No. 08/440,061 filed May 12, 1995, discloses the use of lanreotide for treating hyperamylinemia.
U.S. Application No. 08/852,221 filed May 7, 1997, discloses the use of lanreotide for treating hyperprolactinemia and prolactinomas.
The contents of the foregoing patents and applications are incorporated herein by reference. Summary of the Invention
This invention is directed to a method of treating a disease or condition which comprises administering to a patient in need thereof an effective amount of the compound H-β-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, where the two Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks.
A preferred method of the immediately foregoing method is where the acetate salt of H-β-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 is administered.
A preferred method of the immediately foregoing method is where the disease or condition is selected from the group consisting of VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, hypersecretory diarrhea, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, diabetic neuropathy, meningioma and cancer cachexia.
A preferred method of the immediately foregoing method is where the disease or condition treated is selected from the group consisting of VIPoma, nesidoblastosis, hypersecretory diarrhea, irritable bowel syndrome, small bowel obstruction and diabetic neuropathy.
In another aspect, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the acetate salt of H-β-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 to treat a disease or condition wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks.
Detailed Description
Lanreotide is readily prepared according to the procedure disclosed in U.S. Patent No. 4,853,371 , or the procedure disclosed in U.S. Patent No. 5,411 ,943, the teachings of which are incorporated herein by reference. Lanreotide is currently marketed as the acetate salt in a 30 mg long-acting form and is available from Ipsen Biotech, Paris, France.
As is well known to those skilled in the art, the known and potential uses of somatostatin are varied and multitudinous. Somatostatin is known to be useful in the treatment of the diseases and/or conditions listed hereinbelow. The varied uses of somatostatin may be summarized as follows: Cushings Syndrome (see Clark, R.V. et al, Clin. Res. 38, p. 943A, 1990); gonadotropinoma (see Ambrosi B., et al., Acta Endocr. (Copenh.) 122, 569-576, 1990); hyperparathyroidism (see Miller, D., et al., Canad. Med. Ass. J., Vol. 145, pp. 227-228, 1991); Paget's disease (see, Palmie , G.M.A., et al., J. of Bone and Mineral Research, 7, (Suppl. 1), p. S240 (Abs. 591 ), 1992); VIPoma (see Koberstein, B., et al., Z. Gastroenterology, 28, 295-301 , 1990 and Christensen, O, Acta Chir. Scand. 155. 541-543, 1989); nesidioblastosis and hyperinsulinism (see Laron, Z., Israel J. Med. Sci., 26, No. 1 , 1-2, 1990, Wilson, D.C., Irish J. Med. Sci., 158, No. 1 , 31-32, 1989 and Micic, D., et al., Digestion, 16, Suppl. 1.70. Abs. 193, 1990); gastrinoma (see Bauer, F.E., et al., Europ. J. Pharmacol., 183, 55 1990); Zollinger-Ellison Syndrome (see Mozell, E., et al., Surg. Gynec. Obstet., 170. 476-484, 1990); hypersecretory diarrhea related to AIDS and other conditions (due to AIDS, see Cello, J.P., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A163 1990; due to elevated gastrin-releasing peptide, see Alhindawi, R., et al., Can. J. Surg., 33, 139-142, 1990; secondary to intestinal graft vs. host disease, see Bianco J.A., et al., Transplantation, 49, 1194-1195, 1990; diarrhea associated with chemotherapy, see Petrelli, N., et al., Proc. Amer. Soc. Clin. Oncol., Vol. 10, P 138, Abstr. No. 417 1991); irritable bowel syndrome (see O'Donnell, L.J.D., et al., Aliment. Pharmacol. Therap., Vol. 4., 177-181 , 1990); pancreatitis (see Tulassay, Z., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A238, 1990); Crohn's Disease (see Fedorak, R.N., et al., Can. J. Gastroenterology, 3, No. 2, 53-57, 1989); systemic sclerosis (see Soudah, H., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A129, 1990); thyroid cancer (see Modigliani, E., et al., Ann., Endocr. (Paris), 50, 483-488, 1989); psoriasis (see Camisa, C, et al., Cleveland Clinic J. Med., 57 ,No. 1 , 71-76, 1990); hypotension (see Hoeldtke, R.D., et al., Arch. Phys. Med. Rehabil., 69, 895-898, 1988 and Kooner, J.S., et al., Brit. J. Clin. Pharmacol., 28, 735P-736P, 1989); panic attacks (see Abelson, J.L., et al., Clin. Psychopharmacol., 10, 128-132, 1990); sclerodoma (see Soudah, H., et al., Clin. Res., Vol. 39, p. 303A, 1991 ); small bowel obstruction (see Nott, D.M., et al., Brit. J. Surg., Vol. 77, p. A691 , 1990); gastroesophageal reflux (see Branch, M.S., et al., Gastroenterology, Vol. 100, No. 5, Part 2 Suppl., p. A425, 1991); duodenogastric reflux (see Hasler, W., et al., Gastroenterology, Vol. 100, No. 5, Part 2, Suppl., p. A448, 1991 ); Graves' Disease (see Chang, T.C., et al., Brit. Med. J., 304, p. 158, 1992); polycystic ovary disease (see Prelevic, G.M., et al., Metabolism Clinical and Experimental, 41 , Suppl. 2, pp 76-79, 1992); upper gastrointestinal bleeding (see Jenkins, S.A., et al., Gut., 33, pp. 404-407, 1992 and Arrigoni, A., et al., American Journal of Gastroenterology, 87, p. 1311 , (abs. 275), 1992); pancreatic pseudocysts and ascites (see Hartley, J.E., et al., J. Roy. Soc. Med., 85, pp. 107-108, 1992); leukemia (see Santini, et al., 78, (Suppl. 1), p. 429A (Abs. 1708), 1991); meningioma (see Koper, J.W., et al., J. Clin. Endocr. Metab., 74, pp. 543-547, 1992); and cancer cachexia (see Bartlett, D.L., et al., Surg. Forum., 42, pp. 14-16, 1991). The contents of the foregoing references are incorporated herein by reference.
Surprisingly, the Applicant has now discovered that lanreotide itself was particularly useful in treating the conditions, disorders and disease noted hereinabove.
The usefulness of lanreotide in the various disclosed new medical uses can be better understood through the results of tests relating to the treatment of upper gastrointestinal bleeding.
Lanreotide or a pharmaceutically-acceptable salt thereof can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria- retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax. Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 25 ?g/kg/day to 100 mg/kg/day of body weight daily are administered as a single dose or divided into multiple doses to humans and other animals, e.g., mammals, to obtain the desired therapeutic effect. A preferred general dosage range is 250 ?g/kg/day to 5.0 mg/kg/day of body weight daily which can be administered as a single dose or divided into multiple doses.
Further, Lanreotide can be administered in a sustained release composition such as those described in the following patents. Among those formulations, 14-day or 28-day slow release formulations will be preferred. U.S. Patent No. 5,672,659 teaches sustained release compositions comprising Lanreotide and a polyester. U.S. Patent No. 5,595,760 teaches sustained release compositions comprising Lanreotide in a gelable form. U.S. Application No. 08/929,363 filed September 9, 1997, teaches polymeric sustained release compositions comprising Lanreotide and chitosan. U.S. Application No. 08/740,778 filed November 1 , 1996, teaches sustained release compositions comprising Lanreotide and cyclodexthn. U.S. Application No. 09/015,394 filed January 29, 1998, teaches absorbable sustained release compositions of Lanreotide. The contents of the foregoing patents and applications are incorporated herein by reference.
The use of immediate or of sustained release compositions depends on the type of indications aimed at. If the indication consists of an acute or over- acute disorder, a treatment with an immediate form will be preferred over the same with a prolonged release composition. On the contrary, for preventive or long-term treatments, a prolonged release composition will generally be preferred.
Typically, to the indication upper gastrointestinal bleeding will correspond an acute or over-acute treatment with a dosage of 80 to 120 ?g/day per person during approximately 5 days. After endoscopical treatment, preventive treatment against recurrence can be performed using lanreotide sustained release forms as an adjuvant to usual treatments; for this type of treatment, 14-day sustained release forms with a total dosage of approximately 30 mg lanreotide or 28-day lanreotide forms can be used.
For other indications than upper gastrointestinal bleeding, which correspond rather long term treatments, 14-day sustained release forms with a total dosage of approximately 30 mg lanreotide or 28-day lanreotide forms will be adequate.

Claims

Claims
1. A method of treating a disease or condition which comprises administering to a patient in need thereof an effective amount of the compound H-╬▓-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2, where the two Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks.
2. A method according to claim 1 wherein the acetate salt of H-╬▓-D-
Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 is administered.
3. A method according to claim 2 wherein the disease or condition is selected from the group consisting of VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, hypersecretory diarrhea, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, diabetic neuropathy, meningioma and cancer cachexia.
4. A method according to claim 3 wherein the disease or condition treated is selected from the group consisting of VIPoma, nesidoblastosis, hypersecretory diarrhea, irritable bowel syndrome, small bowel obstruction and diabetic neuropathy.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the acetate salt of H-╬▓-D-Nal-Cys- Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 to treat a disease or condition wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks.
PCT/US1999/017294 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue WO2000006185A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA002335654A CA2335654A1 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
JP2000562039A JP2002521456A (en) 1998-07-30 1999-07-29 How to use somatostatin analogs
NZ509348A NZ509348A (en) 1998-07-30 1999-07-29 Use of a somatostatin analogue Lanreotide
AU52447/99A AU770193B2 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
PL99346361A PL346361A1 (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
KR1020017001277A KR20010071071A (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue
HU0102839A HUP0102839A3 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue and pharmaceutical compositions comprising thereof
BR9912609-5A BR9912609A (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analog
EP99937658A EP1100532A2 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue
MXPA01000969A MXPA01000969A (en) 1998-07-30 1999-07-29 Methods of using a somatostatin analogue.
IL14083799A IL140837A0 (en) 1998-07-30 1999-07-29 Method of using lanreotide, a somatostatin analogue
NO20010481A NO324123B1 (en) 1998-07-30 2001-01-29 Use of lanreotide, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition
AU2004201783A AU2004201783A1 (en) 1998-07-30 2004-04-29 Methods of using a somatostatin analogue
IL181349A IL181349A0 (en) 1998-07-30 2007-02-15 Method of using lanreotide, a somatostatin analogue for preparation of medicaments for treating diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9469398P 1998-07-30 1998-07-30
US12652598A 1998-07-30 1998-07-30
US09/126,525 1998-07-30
US60/094,693 1998-07-30

Publications (2)

Publication Number Publication Date
WO2000006185A2 true WO2000006185A2 (en) 2000-02-10
WO2000006185A3 WO2000006185A3 (en) 2000-08-03

Family

ID=26789150

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017294 WO2000006185A2 (en) 1998-07-30 1999-07-29 Methods of using lanreotide, a somatostatin analogue

Country Status (16)

Country Link
EP (1) EP1100532A2 (en)
JP (1) JP2002521456A (en)
KR (1) KR20010071071A (en)
CN (1) CN1334742A (en)
AR (1) AR023633A1 (en)
AU (2) AU770193B2 (en)
BR (1) BR9912609A (en)
CA (1) CA2335654A1 (en)
CZ (1) CZ2001157A3 (en)
HU (1) HUP0102839A3 (en)
IL (2) IL140837A0 (en)
MX (1) MXPA01000969A (en)
NO (1) NO324123B1 (en)
NZ (1) NZ509348A (en)
PL (1) PL346361A1 (en)
WO (1) WO2000006185A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2002009739A1 (en) * 2000-07-27 2002-02-07 Novartis Ag Treatment of ocular disorders with somatostatin analogues
WO2002083895A2 (en) * 2001-04-18 2002-10-24 University College London New gene from crassostera gigas
US9220760B2 (en) 2001-03-06 2015-12-29 The Administrators Of The Tulane Educational Fund Method of modulating the proliferation of medullary thyroid carcinoma cells
US9579364B2 (en) 2002-01-22 2017-02-28 New York University Methods for treating benign prostatic hypertrophy (BPH)
EP3241560A1 (en) 2008-11-17 2017-11-08 Ipsen Bioinnovation Limited Suppression of cancer
EP3473643A1 (en) 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatemnt of cancer
EP3590956A1 (en) 2008-06-12 2020-01-08 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101935252B (en) * 2010-07-29 2013-01-30 广东省农业科学院科技情报研究所 Landscape plant growth retardant and preparation method thereof
MX362533B (en) * 2012-04-12 2019-01-23 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors.
CN105168115A (en) * 2015-09-02 2015-12-23 中国药科大学 Oral medication path of somatostatin analogue polypeptide drug
WO2017212390A1 (en) * 2016-06-06 2017-12-14 Emcure Pharmaceuticals Ltd, Process for lanreotide acetate preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5506339A (en) * 1989-12-08 1996-04-09 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
US5688530A (en) * 1989-07-07 1997-11-18 Novartis Ag Sustained release formulations of water soluble peptides
WO1998008529A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
WO1998010786A2 (en) * 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
WO1998051332A1 (en) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5688530A (en) * 1989-07-07 1997-11-18 Novartis Ag Sustained release formulations of water soluble peptides
US5506339A (en) * 1989-12-08 1996-04-09 The Administrators Of The Tulane Educational Fund Octapeptide analogs of somatostatin having threonine at the sixth position
WO1998008529A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
WO1998010786A2 (en) * 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
WO1998051332A1 (en) * 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ANTHONY L B ET AL: "Case report: lanreotide in the management of hypercalcemia of malignancy." AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol. 309, no. 6, June 1995 (1995-06), pages 312-314, XP000867465 *
BARTLETT D L ET AL: "Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia." SURGERY (ST LOUIS), vol. 118, no. 1, July 1995 (1995-07), pages 87-97, XP000907234 *
CHANSON P: "Traitements médicamenteux des adénomes hypophysaires." REVUE DU PRATICIEN, vol. 46, 15 June 1996 (1996-06-15), pages 1509-1513, XP000907252 *
HASLER W ET AL: "ROLE OF THE PYLORUS IN THE PREVENTION OF DUODENO-GASTRIC REFLUX EFFECTS OF THE SOMATOSTATIN ANALOG." GASTROENTEROLOGY, vol. 100, no. 5, 19 - 22 May 1991, page A448 XP000866191 cited in the application *
HOELDTKE R D ET AL: "Treatment of orthostatic hypotension with midodrine and octreotide." JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 83, no. 2, February 1998 (1998-02), pages 339-343, XP000907222 *
JAFFRAIN-REA ML ET AL: "Visual improvement during octreotide therapy in a case of episellar meningioma." CLINICAL NEUROLOGY AND NEUROSURGERY, vol. 100, no. 1, March 1998 (1998-03), pages 40-43, XP000907228 *
KANG S & MISHKIN F S: "Visualization of Paget's disease during somatostatin receptor scintigraphy." CLINICAL NUCLEAR MEDICINE, vol. 24, no. 11, November 1999 (1999-11), pages 900-902, XP000907230 *
KHOO D ET AL: "Palliation of malignant intestinal obstruction using octreotide" EUROPEAN JOURNAL OF CANCER, vol. 30A, no. 1, 1994, pages 28-30, XP000866064 *
KIRK J M W ET AL: "Somatostatin analogue in short term management of hyperinsulinism" ARCHIVES OF DISEASE IN CHILDHOOD, vol. 63, no. 12, 1988, page 1493-1494 XP002053035 *
LAMRANI A ET AL: "Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans." BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 43, no. 1, January 1997 (1997-01), pages 65-70, XP000870053 *
MOSDELL K W ET AL: "Emerging indications for octreotide therapy, Part 1." AMERICAN JOURNAL OF HOSPITAL PHARMACY, vol. 51, no. 9, 1 May 1994 (1994-05-01), pages 1184-1192, XP000866264 *
MOTTET C ET AL: "Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study." HEPATOLOGY, vol. 27, no. 4, April 1998 (1998-04), pages 920-925, XP000870061 *
ONO, MASASHI ET AL: "Effects of octreotide acetate treatment for scleroderma bowel." KAWASAKI MEDICAL JOURNAL, vol. 22, no. 4, 1996, pages 233-237, XP000866213 *
PAVLOVIC M. ET AL: "Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide." ARCHIVES OF DERMATOLOGY, vol. 131, no. 10, October 1995 (1995-10), page 1207-1209 XP000866063 *
RIEU M ET AL: "Paradoxical effect of somatostatin analogues on the ectopic secretion of corticotropin in two cases of small cell lung carcinoma." HORMONE RESEARCH, vol. 39, no. 5-6, November 1993 (1993-11), pages 207-212, XP000907231 *
SOBHANI I ET AL: "Lanreotide inhibits human jejunal secretion induced by prostaglandin E1 in healthy volunteers." BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 41, no. 2, February 1996 (1996-02), pages 109-114, XP000870052 *
SRKALOVIC G ET AL: "EVALUATION OF RECEPTORS FOR SOMATOSTATIN IN VARIOUS TUMORS USING DIFFERENT ANALOGS" JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 70, no. 3, March 1990 (1990-03), pages 661-669, XP000907224 *
WECKBECKER G ET AL: "SOMATOSTATIN ANALOGS FOR DIAGNOSIS AND TREATMENT OF CANCER" PHARMACOLOGY AND THERAPEUTICS, vol. 60, no. 2, 1994, pages 245-264, XP002072560 *
WOLTERING E A ET AL: "DETECTION OF OCCULT GASTRINOMAS WITH IODINE 125-LABELED LANREOTIDE AND INTRAOPERATIVE GAMMA-DETECTION" SURGERY, vol. 116, no. 6, December 1994 (1994-12), pages 1139-1147, XP000866097 *
ZEILKE A ET AL: "Octreotide: Effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial." SURGERY (ST LOUIS), vol. 121, no. 6, June 1997 (1997-06), pages 606-610, XP000907227 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2002009739A1 (en) * 2000-07-27 2002-02-07 Novartis Ag Treatment of ocular disorders with somatostatin analogues
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
US9220760B2 (en) 2001-03-06 2015-12-29 The Administrators Of The Tulane Educational Fund Method of modulating the proliferation of medullary thyroid carcinoma cells
WO2002083895A2 (en) * 2001-04-18 2002-10-24 University College London New gene from crassostera gigas
WO2002083895A3 (en) * 2001-04-18 2003-02-06 Univ London New gene from crassostera gigas
US9579364B2 (en) 2002-01-22 2017-02-28 New York University Methods for treating benign prostatic hypertrophy (BPH)
EP3473643A1 (en) 2008-06-12 2019-04-24 Ipsen Bioinnovation Limited Fusion proteins for use in the treatemnt of cancer
EP3590956A1 (en) 2008-06-12 2020-01-08 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
EP3241560A1 (en) 2008-11-17 2017-11-08 Ipsen Bioinnovation Limited Suppression of cancer

Also Published As

Publication number Publication date
JP2002521456A (en) 2002-07-16
HUP0102839A2 (en) 2002-01-28
AR023633A1 (en) 2002-09-04
NO20010481D0 (en) 2001-01-29
CA2335654A1 (en) 2000-02-10
AU770193B2 (en) 2004-02-12
IL181349A0 (en) 2007-07-04
AU5244799A (en) 2000-02-21
MXPA01000969A (en) 2003-04-07
AU2004201783A1 (en) 2004-05-27
WO2000006185A3 (en) 2000-08-03
PL346361A1 (en) 2002-02-11
KR20010071071A (en) 2001-07-28
CN1334742A (en) 2002-02-06
HUP0102839A3 (en) 2002-02-28
CZ2001157A3 (en) 2002-02-13
IL140837A0 (en) 2002-02-10
NO20010481L (en) 2001-03-21
BR9912609A (en) 2001-05-02
EP1100532A2 (en) 2001-05-23
NO324123B1 (en) 2007-08-27
NZ509348A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
AU770193B2 (en) Methods of using a somatostatin analogue
AU2005318454B2 (en) Sustained release formulation comprising bisphosphonate
US20080242609A1 (en) Composition for the therapy of diabetes mellitus and adiposity
NO317867B1 (en) Cyclic somatostatin hexapeptides, pharmaceutical compositions comprising such, and the use of such hexapeptides for the preparation of pharmaceutical compositions.
US20070027073A1 (en) Long-acting derivatives of pyy agonists
US20190201541A1 (en) Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
US6362164B1 (en) Combination of a somatostatin analogue and a rapamycin
US6150333A (en) Methods of using a somatostatin analogue
US20130035286A1 (en) Pharmaceutical Composition Comprising Cyclic Somatostatin Analogues
EP1291022A1 (en) Methods of using lanreotide, a somatostatin analogue
ZA200100793B (en) Methods of using a somatostatin analogue.
EP0657174A1 (en) Use of somatostatin
US20040198653A1 (en) Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof
AU2002316361A1 (en) Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof
JPH04210998A (en) Inhibition of endotherial ion secretion from digestive tract by peptide derivative

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808953.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 140837

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2001-157

Country of ref document: CZ

Ref document number: 1999937658

Country of ref document: EP

Ref document number: 509348

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 52447/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2335654

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000969

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 562039

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/00793

Country of ref document: ZA

Ref document number: 200100793

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020017001277

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999937658

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09744846

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017001277

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-157

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999937658

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017001277

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 52447/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 181349

Country of ref document: IL

WWR Wipo information: refused in national office

Ref document number: PV2001-157

Country of ref document: CZ